A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/15/2001	CA2408399A1 Infrared thermography and methods of use
11/15/2001	CA2408343A1 N-acyltetrahydroisoquinoline derivatives
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408293A1 Novel vitronectin receptor antagonists
11/15/2001	CA2408290A1 New polycyclic indanylimidazoles with alpha2 adrenergic activity
11/15/2001	CA2408288A1 Novel substituted diamine derivatives useful as motilin antagonists
11/15/2001	CA2408255A1 Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
11/15/2001	CA2408253A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/15/2001	CA2408236A1 Peptide deformylase inhibitors
11/15/2001	CA2408234A1 Peptide deformylase inhibitors
11/15/2001	CA2408220A1 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408196A1 Sphingosine kinase and uses thereof
11/15/2001	CA2408156A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
11/15/2001	CA2408152A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/15/2001	CA2408112A1 Skin protectant spray compositions
11/15/2001	CA2408106A1 Opioid antagonist compositions and dosage forms
11/15/2001	CA2408098A1 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
11/15/2001	CA2408051A1 Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407962A1 Cosmetic agents containing 2-furanone derivatives
11/15/2001	CA2407886A1 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
11/15/2001	CA2407852A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2407817A1 Anthranilamides and their use as pharmaceutical agents
11/15/2001	CA2407789A1 Benzoxazines for use in the treatment of parkinson's disease
11/15/2001	CA2407697A1 Felbamate derived compounds
11/15/2001	CA2406634A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
11/15/2001	CA2406633A1 Anti-viral pyrimidine nucleoside analogues
11/15/2001	CA2406549A1 R-eliprodil for treating glaucoma
11/15/2001	CA2406512A1 Pharmaceutical compounds for treating copd
11/15/2001	CA2405968A1 Hydantoin derivatives with affinity for somatostatin receptors
11/15/2001	CA2405758A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
11/15/2001	CA2404987A1 (e)-7(4-fluorophenyl)-6isopropyl2-mesylaminopyrimidin-5-y)-(3r,5s)-dihydroxyhept-6-enoic acid.
11/15/2001	CA2395314A1 Compounds and methods for modulating cerebral amyloid angiopathy
11/14/2001	EP1154022A1 Novel substance originating in basidiomycete culture, process for producing the same and use thereof
11/14/2001	EP1154019A2 G-protein coupled receptor (HFGAN72X)
11/14/2001	EP1153940A1 Polymer combining with phosphoric acid and preparation containing the same
11/14/2001	EP1153931A1 Shortened-chain polynucleotides and process for the preparation thereof
11/14/2001	EP1153924A2 Substituted 1,3-oxathiolanes with antiviral properties
11/14/2001	EP1153922A1 Heterodiazinone derivatives
11/14/2001	EP1153921A2 Cyclic ureas and analogues useful as retroviral protease inhibitors
11/14/2001	EP1153620A2 Solid compositions exhibiting selective binding to dissolved iron
11/14/2001	EP1153618A1 Use of oxidized cellulose as free radical scavenger
11/14/2001	EP1153614A1 Ophthalmic compositions
11/14/2001	EP1153613A1 Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
11/14/2001	EP1153605A1 Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa
11/14/2001	EP1153604A1 Adp-ribosylation inhibitors and remedies for endotoxic bacterial enteric infection containing proanthocyanidin as the active ingredient
11/14/2001	EP1153603A2 New treatments using phenethylamine derivatives
11/14/2001	EP1153601A1 Skin preparations for external use
11/14/2001	EP1153548A1 Vitamin k2 containing food product
11/14/2001	EP1153546A1 Novel use of delta-aminolevulinic acid for prevention and treatment of infection by pathogenic microorganisms and parasite
11/14/2001	EP1153129A1 Method of treating restenosis by antisense targeting of c-myc
11/14/2001	EP1153128A1 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
11/14/2001	EP1153038A1 Therapeutics and diagnostics based on a il-1b mutation
11/14/2001	EP1153036A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
11/14/2001	EP1153034A1 Growth hormone secretagogues
11/14/2001	EP1153033A1 Method for purifying a red fruit extract containing anthocyanosides
11/14/2001	EP1153024A1 2-amino-6-anilino-purines and their use as medicaments
11/14/2001	EP1153022A1 Prothease inhibitors
11/14/2001	EP1153017A1 Bicyclic compounds and their use as integrin receptor ligands
11/14/2001	EP1153015A1 Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases
11/14/2001	EP1153014A2 Beta-alanine derivatives
11/14/2001	EP1153013A2 5-ht1f agonists
11/14/2001	EP1153010A1 $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME
11/14/2001	EP1152772A2 Liposome composition and method for administration of a radiosensitizer
11/14/2001	EP1152771A2 Adjuvant and cell maturation agent
11/14/2001	EP1152765A1 Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
11/14/2001	EP1152764A1 Compositions and methods for use in targeting vascular destruction
11/14/2001	EP1152763A2 Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
11/14/2001	EP1152762A1 Use of desoxypeganine in the treatment of alzheimer's dementia
11/14/2001	EP1152761A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
11/14/2001	EP1152760A1 Use of 4-amino pyridine for treatment of peripheral neuropathies
11/14/2001	EP1152759A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
11/14/2001	EP1152758A1 Use of lipoic acid in combination with ascorbic acid in the treatment of cancer
11/14/2001	EP1152757A2 Connective tissue softening
11/14/2001	EP1152756A1 Anticonvulsant derivatives useful in treating autism
11/14/2001	EP1152755A1 Essential fatty acids in the prevention of cardiovascular events
11/14/2001	EP1152754A1 Topic tricyclic antidepressants as analgesics
11/14/2001	EP1152753A1 Combinations of formoterol and fluticasone propionate for asthma
11/14/2001	EP1152752A1 Methods for preventing graft rejection and ischemia-reperfusion injury
11/14/2001	EP1152751A1 Desoxypeganine transdermal therapeutic system
11/14/2001	EP1152750A1 Spontaneously dispersible n-benzoyl staurosporine compositions
11/14/2001	EP1152748A1 Method and composition for treating acne
11/14/2001	EP1152745A2 Synergistic antimicrobial skin washing compositions
11/14/2001	EP1152743A1 Skin sanitizing compositions
11/14/2001	EP1152731A1 A skin care composition that mediates cell to cell communication
11/14/2001	EP1152723A1 Enzymatic treatment and prevention of hypertrophic skin
11/14/2001	EP1125575A9 Perfusate preparation for ophthalmic operation
11/14/2001	EP1021437B1 Arylsulfonylimidazolone derivatives as an antitumor agent
11/14/2001	EP1003484B1 Improved multiparticulate tablet with quick disintegration
11/14/2001	EP0980250B1 Plant extracts for the treatment of increased bone resorption
11/14/2001	EP0975581B1 Solid compositions suitable for oral administration comprising l-carnitine or alkanoyl-l-carnitine choline tartrate
11/14/2001	EP0971879B1 Solid compositions suitable for oral administration comprising l-carnitine and alkanoyl-l-carnitine magnesium tartrate
11/14/2001	EP0956016A4 Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
11/14/2001	EP0952826B1 Idebenone containing combination agent for treating alzheimer's disease
11/14/2001	EP0923942B1 5alpha-REDUCTASE INHIBITORY PREPARATION FOR ORAL ADMINISTRATION, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF
11/14/2001	EP0922071B1 Polycarboxylic based cross-linked copolymers
11/14/2001	EP0904081B1 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
11/14/2001	EP0894002A4 Novel peptides which inhibit complement activation

1 ... 5968 5969 5970 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 ... 7860